Latest news
‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit - BioPharma DiveBioPharma Dive · Fri, 07 Aug 2026 15:02:34 GMTReplimune rebounds to win FDA approval of melanoma drug - BioPharma DiveBioPharma Dive · Thu, 06 Aug 2026 21:16:19 GMTJ&J pharma leader to retire; Krystal slumps on gene therapy miss - BioPharma DiveBioPharma Dive · Tue, 04 Aug 2026 14:35:26 GMTSanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs - BioPharma DiveBioPharma Dive · Fri, 31 Jul 2026 15:18:11 GMTReplimune melanoma drug wins support of FDA panel - BioPharma DiveBioPharma Dive · Thu, 30 Jul 2026 07:00:00 GMTFDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data - Yahoo FinanceYahoo Finance · Wed, 29 Jul 2026 07:00:00 GMT